Wilson Troy Edward Sells Shares of Puma Biotechnology

On June 12, 2026, Wilson Troy Edward, an insider at Puma Biotechnology, Inc. (NasdaqGS: PBYI), sold 10,800 shares. The shares were sold at an average price of $7.20, totaling approximately $77,760. This transaction was executed under a pre-arranged trading plan, known as Rule 10b5-1.

Insider Buying and Selling at Puma Biotechnology, Inc.

Alongside Wilson Troy Edward's sale, several other insiders also made transactions on June 12, 2026. Allison Dorval sold 11,610 shares, Brian Stuglik sold 8,100 shares, Adrian Senderowicz sold 27,000 shares, and Jay Moyes sold 22,000 shares, all at an average price of $7.20. These transactions were also part of planned trading activities. Notably, Jay Moyes made an additional purchase of 27,000 shares on June 11, 2026.

Other Institutional Activity in Puma Biotechnology

ACORN Capital Advisors, LLC maintained its position in Puma Biotechnology with 4,131,299 shares, valued at approximately $26.4 million. BlackRock, Inc. trimmed its holdings by 43,636 shares, ending with 3,598,952 shares worth about $23 million. Acadian Asset Management LLC increased its stake by 16,936 shares, bringing its total to 2,041,759 shares valued at $13 million. Renaissance Technologies LLC reduced its position by 181,400 shares, now holding 1,942,413 shares valued at $12.4 million. American Century Companies Inc boosted its stake significantly by 266,209 shares to a total of 1,916,346 shares, worth $12.2 million.

Puma Biotechnology Stock Snapshot

Shares of Puma Biotechnology (NasdaqGS: PBYI) traded at around $7.33. The company has a market capitalization of $359.9 million and a P/E ratio of 14.73. Over the past year, the stock has fluctuated between a low of $3.03 and a high of $7.90. Its 50-day moving average is $7.25, while the 200-day moving average is $6.09. Puma Biotechnology has a current ratio of 2.38 and a quick ratio of 2.14, with a debt-to-equity ratio of 12.42.

Recent Earnings

In its latest earnings report, Puma Biotechnology reported revenue of $227.2 million, showing a slight decline of 2.6% compared to the previous period. The company achieved a net margin of 10.7% and a return on equity of 21.6%. Earnings per share stood at $0.48. The next earnings announcement is scheduled for August 6, 2026.

Analysts Set New Price Targets

On February 28, 2025, HC Wainwright & Co. reiterated its 'buy' rating for Puma Biotechnology with a price target of $7. Meanwhile, TD Cowen maintained a 'hold' rating with a $4 target on May 20, 2024. Barclays continues to rate the stock as 'sell' with a target of $2. The consensus target price among analysts is $5, based on one opinion.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company based in Los Angeles, California. The company is led by CEO Mr. Alan H. Auerbach and employs 179 people. Puma focuses on developing and commercializing cancer treatments, including NERLYNX, an oral therapy for HER2-positive breast cancer. The company also works on alisertib, a potential treatment for various cancers. Puma collaborates with several international partners to expand the reach of its products.

Bottom Line

Insider transactions like those seen from Wilson Troy Edward and others at Puma Biotechnology can offer insights into company sentiment, but they are just one piece of the puzzle. Investors also watch institutional activity and analyst ratings to gauge market confidence. The company's upcoming earnings report on August 6, 2026, will provide further clarity on its financial health and future prospects.